Rezolute completes Phase 3 upLIFT enrollment; topline ersodetug data expected mid-December 2026

Rezolute, Inc.

Phase 3 upLIFT fully enrolled 16 participants with insulinoma or non-islet cell tumors causing uncontrolled hypoglycemia; topline results expected mid-December 2026.
Primary endpoint: at least 50% reduction from baseline in IV glucose infusion rate; responder rate must be at least 56% (95% CI 30-80%) for significance.
7 of the first 8 participants met the responder criterion and all 7 fully discontinued IV glucose; the eighth entered hospice and died of cancer progression, counted as a non-responder.
Ersodetug given at 9 mg/kg weekly for 8 weeks as add-on to standard of care; well-tolerated with no drug-related safety findings reported to date.
Company continues expanded access for compassionate use in tumor HI and sees potential to advance both indications in 2027 if outcomes are favorable.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.